NCT00166478已完成2 期
A Prospective Controlled Phase II Study of Preoperative Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 130
- 试验地点
- 2
- 主要终点
- 4 week changes in apoptosis biomarkers
研究概览
简要总结
This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy. Participants will be followed for total of 2 months from the time of starting study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males 40 years of age and older with prostate cancer who are scheduled to undergo surgical removal of the prostate at Mayo Clinic Rochester, Mayo Clinic Jacksonville, or Mayo Clinic Arizona may be eligible for this protocol.
排除标准
- 未提供
结局指标
主要结局
4 week changes in apoptosis biomarkers
次要结局
- 4 week changes in surrogate endpoint biomarkers
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
High humidity decreases symptomatic patent ductus arteriosusJPRN-jRCT1032190068Hirata Michisato30
招募中
2 期
Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer: the ANZadapt studyprostate carcinoma10038597prostate cancerNL-OMON56330eids Universitair Medisch Centrum84
招募中
2 期
Does Olanzapine improve quality of life in incurable cancer patients?CTRI/2022/03/041155ational cancer Institute AIIMS
已完成
2 期
Continued use of Atorvostatin in sepsisSepsis / infection in patients taking statin therapyBlood - Studies of infection and infectious agentsACTRN12605000756628Dr Peter Kruger, Intensive Care Specialist, Princess Alexandra Hospital, Brisbane200
进行中（未招募）
1 期
Phase II clinical trial to evaluate the effect and safety of MSV * in Xerostomia * adult autologous bone marrow mesenchymal stem cellsXerostomia post radiotherapyMedDRA version: 20.0 Level: LLT Classification code 10048223 Term: Xerostomia System Organ Class: 100000004856EUCTR2018-001720-19-ESInstitut de Terapia Regenerativa Tissular S.L. (ITRT)10